Looking at CIRM's Clinical Trials: Focus on Opthalmology

Directors of California's $3 billion research program will receive a briefing later today on the agency's investment in clinical trials, but here is a brief look at what they are going to hear about some of the 27 trials.

Maria Millan, vice president of therapeutics, will make the presentation on the existing trials and has posted 17 slides for her presentation, which focuses on opthalmology. 

Among other things, the slides show that 22 percent of the clinical trial funding involves oncology. Next comes hematology with 14 percent and opthalmology with 13 percent. 

Three awards have been made for phase three trials, four for phase two and 19 for phase one. The agency plans to participate in another 40 clinical trials between now and the end of 2020.

The California Stem Cell Report will carry more on Millan's presentation after it is concluded. 

Today's meeting begins at 9 a.m. PST and can be heard via an audiocast. See the agenda for details.